Makes radioactive medical imaging agents that expire within hours and must be delivered to hospitals on a precise clock.
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 0
- Scale
Makes radioactive medical imaging agents that expire within hours and must be delivered to hospitals on a precise clock.
What this company is and how it runs — written from structure, not news.
Lantheus makes radiopharmaceuticals — drugs used in hospital imaging — whose active ingredients decay within hours of being produced, so the entire business is built around getting the right isotope to the right place before it disappears. The core product, the TechneLite generator, solves this by shipping a column of molybdenum-99 directly to the hospital, where technicians extract fresh technetium-99m each morning on-site, sidestepping the transit window that would otherwise consume most of the isotope's usable life. Because hospitals have already installed the generator hardware, trained their staff on elution procedures, and obtained radiopharmacy licenses tied to that specific product, switching to a competitor means replacing equipment and requalifying with regulators — a burden that keeps most nuclear medicine departments where they are. The one constraint Lantheus cannot engineer around is the molybdenum-99 supply itself, which can only be produced in a small number of aging research reactors worldwide, meaning a multi-site reactor shutdown would render every installed generator inert, regardless of how much manufacturing capacity or logistics infrastructure the company has built.
How does this company make money?
The company sells TechneLite generators and then collects recurring revenue each time a hospital orders a fresh molybdenum-99 replacement column to recharge it. It also sells single-use vials of PYLARIFY and other radiopharmaceuticals, with revenue tied directly to how many procedures hospitals perform. On top of that, it charges licensing fees for AI-powered imaging analysis software that connects to hospital PET/CT systems.
What makes this company hard to replace?
Nuclear medicine departments already have TechneLite generators installed and staff trained specifically on technetium elution procedures — switching to a different supplier means replacing equipment and retraining people. PYLARIFY AI software is integrated directly into hospital PET/CT systems, and changing it requires IT validation cycles that take time and resources. Radiopharmacy licenses are written for specific products, so switching to an alternative agent requires going through a separate regulatory requalification process.
What limits this company?
The only thing that controls how many procedures can happen is the supply of molybdenum-99, and that supply can only come from research reactors — a small, aging group of facilities worldwide. Molybdenum-99 itself decays in about 66 hours, so it cannot be stockpiled. If a major reactor goes offline, fewer generators can be recharged, and the number of patients who can be scanned drops immediately — no matter how much manufacturing capacity or hospital demand exists.
What does this company depend on?
The company cannot operate without molybdenum-99 from nuclear reactors that produce it, fluorine-18 from cyclotrons for agents like PYLARIFY, FDA approval for each specific radiopharmaceutical use, specialized radiopharmacy manufacturing facilities equipped with hot cells to safely handle radioactive materials, and cold-chain transportation networks that can move isotopes without losing them to decay during transit.
Who depends on this company?
Hospital nuclear medicine departments lose the ability to run cardiac stress tests and prostate cancer staging scans when DEFINITY or PYLARIFY are unavailable. Cardiologists cannot evaluate blood flow to the heart without Cardiolite, which forces delays in cardiac procedures. Oncologists lose the precision imaging that PYLARIFY PET scans provide for prostate cancer, making it harder to plan treatment accurately.
How does this company scale?
Once a radiopharmaceutical formulation and its quality control steps are validated at one production site, those same processes can be replicated at other sites. What cannot be automated or scaled freely is the logistics side — every batch requires real-time decay calculations, and production sites must sit geographically close to the hospitals they serve because the isotopes are expiring from the moment they are made.
What external forces can significantly affect this company?
Reactor shutdowns at aging molybdenum-99 production facilities can cause global isotope shortages that no single company can prevent or fix. Changes to Medicare reimbursement rates for nuclear medicine procedures directly affect how much hospitals are willing to spend on diagnostic radiopharmaceuticals. International regulations around shipping nuclear materials, along with homeland security restrictions, can disrupt cross-border isotope supply chains regardless of manufacturing readiness.
Where is this company structurally vulnerable?
If several major molybdenum-99 reactors shut down at the same time — which becomes more likely as aging facilities are retired without new ones coming online to replace them — the TechneLite generators sitting in hospitals become useless metal. No generator can produce technetium-99m without a fresh molybdenum-99 column, and there is no alternative source large enough to keep procedure volumes running.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations have aligned in the up direction: the higher-lows-pattern observation is firing, the ADX observation (sustained directional-movement asymmetry) is in the upper portion of its mapped range, and the OBV-trending-up observation is firing.
Three observations describe the present configuration: a high share of the trailing year's weekly closes were higher than the prior week, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked TTM operating cash flow margin is in the upper peer range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Three balance sheet composition observations have converged at elevated readings: intangible assets are a large share of total assets, goodwill is a large share of total assets, and goodwill is large relative to shareholders equity. Together they describe an asset and equity base heavily composed of non-physical, acquisition-derived line items.
How does this company use capital?
Three working-capital observations align: accounts receivable have increased every year over the trailing three years, inventory turnover is elevated (fast inventory cycling), and payables turnover is elevated (fast supplier payment — the opposite direction from what cash-conversion-cycle optimization usually targets). The three observation describe characteristics of the working-capital lines, not a coherent cycle-optimization profile.
Three observations align: revenue has increased every year over the trailing three years, receivables have increased every year over the trailing four years, and operating cash flow margin is on the industry-benchmarked scale. The picture is concurrent growth in revenue and receivables with peer-relative cash-conversion context.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph